With B-OM results coming soon, and 19 patients of the total patient pool already showing positive results (from interim which will be included in final total, correct?), it seems to me the interim results would have to be totally inconsistent with the rest of the trial to have results that would not be considered a home run. If they are consistent, what will IPIX do with the B platform since this should be the final mid-stage result that they currently have in trials. Will they partner/license each indication separately or will they try to do so with one BP for the entire platform? Any ideas that make sense would be appreciated.